Shots:

• Smiths to receive 2.5M at closing in cash and stock which is currently valued at ~$500M- $1.85B in cash along with liabilities & is eligible for up to $100M in milestones. The transaction is expected to close in H1’22
• The acquisition combines Smiths’ business includes syringes- ambulatory infusion devices- vascular access & vital care products with ICU Medical’s existing businesses to create a leading infusion therapy company with a stronger global reach
• The companies have entered into an option agreement in which Smiths has the right to acquire ICU Medical by entering into a binding share purchase agreement. Additionally- Smith will retain ~ 10% of ICU Medical

| Ref: Globe Newswire | Image: PharmaLive